China Nuokang Bio-Pharma (NKBP) Receives 'Go Private' Bid from Chairman Xue for $5.80/ADS
Tweet
Share
E-mailGet Alerts NKBP Hot Sheet
Join SI Premium – FREE
China Nuokang Bio-Pharma (Nasdaq: NKBP) receives "going private" proposal from Chairman and CEO Baizhong Xue, for $5.80 per ADS. Mr. Xue currently owns about 61.2 percent of the company's ordinary shares.
The company's Board intends to form a special committee to consider the proposal.
Shares were halted following the release of the news.
The company's Board intends to form a special committee to consider the proposal.
Shares were halted following the release of the news.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Holcim said to acquire part of James Hardie's EU business
- General Fusion lists on Nasdaq via SPAC merger with $150M in cash
- Holcim to acquire Fermacell from James Hardie for EUR 840M
Create E-mail Alert Related Categories
Mergers and Acquisitions, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
